<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Is Masked Hypertension an underlying Cause of Unexplained Left Ventricle Hypertrophy?

dc.contributor.authorYilmaz, O. Caglar
dc.contributor.authorOzkan, Selcuk
dc.date.accessioned2026-10-09T21:49:12Z
dc.date.issued2021
dc.departmentYüksek İhtisas Üniversitesi
dc.description.abstractObjectives Unexplained left ventricular hypertrophy (ULVH) is defined as increased wall thickness in the absence of conditions that predispose to hypertrophy. The aim of this study was to evaluate the rate of masked hypertension in patient with unexplained left ventricle hypertrophy. Method A total of 120 consecutive unexplained left ventricle hypertrophy patients without overt hypertension and diabetes and 121 healthy control subjects were included in the study. After a complete medical history and laboratory examination, patients' height, weight, waist circumference heart rate, and office blood pressure were recorded. All subjects underwent ambulatory blood pressure monitoring, and transthoracic echocardiography. Results Mean age were similar between patients with ULVH and controls. There was no significant difference in total cholesterol, HDL, LDL cholesterol and triglyceride levels, left ventricle ejection fraction, between the groups. Prevalence of Masked hypertension was significantly higher in patients with ULVH than controls (28.3% vs 6.6%,p< .001). Left ventricular mass index (141.9 +/- 16.8 g/cm(2)vs. 67.3 +/- 10.3 g/cm(2),p< .001) was significantly higher in masked hypertensive patients with ULVH compared to normotensive ULVH and control subjects. Conclusion In this study, we found high prevalence of masked hypertension in ULVH patients. Patients with ULVH should be screened by ABPM to detect possible masked hypertension.
dc.identifier.doi10.1080/10641963.2020.1825729
dc.identifier.endpage141
dc.identifier.issn1064-1963
dc.identifier.issn1525-6006
dc.identifier.issue2
dc.identifier.pmid32985273
dc.identifier.scopus2-s2.0-85091613931
dc.identifier.scopusqualityQ2
dc.identifier.startpage138
dc.identifier.urihttps://doi.org/10.1080/10641963.2020.1825729
dc.identifier.urihttps://hdl.handle.net/20.500.12794/3636
dc.identifier.volume43
dc.identifier.wosWOS:000573126500001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.indekslendigikaynak.digerScience Citation Index Expanded (SCI-EXPANDED)
dc.language.isoen
dc.publisherTaylor & Francis Inc
dc.relation.ispartofClinical and Experimental Hypertension
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.relation.sdgGoal-03: Good Health and Well-Being
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260922
dc.subjectHypertension
dc.subjectMasked Hypertension
dc.subjectUnexplained Left Ventricle Hypertrophy
dc.subjectAmbulatory Blood Pressure Monitoring
dc.subjectHypertrophy
dc.titleIs Masked Hypertension an underlying Cause of Unexplained Left Ventricle Hypertrophy?
dc.typeArticle

Files